FAM111A

Chr 11AD

FAM111 trypsin like peptidase A

Also known as: GCLEB, KCS2

The protein is a single-stranded DNA-binding serine protease that removes toxic DNA-protein cross-links during DNA synthesis and is required for proper DNA replication. Mutations cause Kenny-Caffey syndrome type 2 and the more severe gracile bone dysplasia, both characterized by short stature, hypoparathyroidism, bone development abnormalities, and hypocalcemia. Inheritance is autosomal dominant.

OMIMResearchSummary from RefSeq, OMIM, UniProt
GOFmechanismADLOEUF 1.952 OMIM phenotypes
Clinical SummaryFAM111A
🧬
Gene-Disease Validity (ClinGen)
FAM111A-related skeletal dysplasia · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.95LOEUF
pLI 0.002
Z-score -1.21
OE 2.09 (0.661.95)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
-0.02Z-score
OE missense 1.00 (0.921.10)
324 obs / 322.9 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE2.09 (0.661.95)
00.351.4
Missense OE1.00 (0.921.10)
00.61.4
Synonymous OE0.95
01.21.6
LoF obs/exp: 3 / 1.4Missense obs/exp: 324 / 322.9Syn Z: 0.41
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveFAM111A-related Kenny-Caffey syndromeGOFAD
DN
0.75top 25%
GOF
0.4776th %ile
LOF
0.2289th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOF1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFFAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human diseasePMID:32776417

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

FAM111A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →